Sangamo Therapeutics (SGMO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 39,552 | 57,800 | 176,232 | 111,299 | 110,701 |
| Gross Profit | 39,552 | 57,800 | 176,232 | 111,299 | 110,701 |
| Operating Expenses | 160,791 | 161,769 | 450,237 | 312,580 | 294,038 |
| Operating Income | -121,239 | -103,969 | -274,005 | -201,281 | -183,337 |
| Other Income | -2,261 | 5,861 | 11,102 | 9,432 | 5,346 |
| Pre-tax Income | -123,500 | -98,108 | -262,903 | -191,849 | -177,991 |
| Income Tax | -568 | -167 | -5,072 | 429 | 306 |
| Net Income Continuous | -122,932 | -97,941 | -257,831 | -192,278 | -178,297 |
| Minority Interests | N/A | N/A | N/A | N/A | -11 |
| Net Income | $-122,932 | $-97,941 | $-257,831 | $-192,278 | $-178,286 |
| EPS Basic Total Ops | -0.44 | -0.49 | -1.48 | -1.25 | -1.23 |
| EPS Basic Continuous Ops | -0.44 | -0.49 | -1.48 | -1.25 | -1.23 |
| EPS Diluted Total Ops | -0.44 | -0.49 | -1.48 | -1.25 | -1.23 |
| EPS Diluted Continuous Ops | -0.44 | -0.49 | -1.48 | -1.25 | -1.23 |
| EPS Diluted Before Non-Recurring Items | -0.40 | -0.49 | -0.59 | -1.25 | -1.23 |
| EBITDA(a) | $-113,637 | $-94,608 | $-164,657 | $-181,961 | $-162,855 |